HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel modified t-PA, E-6010, induces faster recovery of ventricular function after coronary thrombolysis than native t-PA in a canine thrombosis model.

Abstract
Using the centerline method in a canine model, we compared left ventricular function after coronary thrombolysis induced by a novel modified recombinant tissue plasminogen activator (rt-PA) (E6010: 84Cys-->84Ser) to that induced by rt-PA or urokinase. Thirty minutes after occlusion, a bolus injection of E6010 (0.2 mg/kg) or a continuous infusion of either rt-PA (0.6 mg/kg over 1 h) or urokinase (0.38 mg/kg over 1 h) was administered intravenously. Animals with sustained copper coil-occlusion served as non-reperfused controls. Left ventricular ejection fraction and regional wall motion (expressed as the infarction chord number; ie, the number of chords < -2SD among chords 12-66) were 42 +/- 5%** and 5 +/- 3,** respectively, in the E6010 group, 31 +/- 8% and 16 +/- 12 in the rt-PA group, and 31 +/- 2% and 32 +/- 13 in the urokinase group 1 h after reperfusion, indicating earlier recovery of left ventricular function after thrombolysis in the E6010 group than in the rt-PA and urokinase groups (**p < 0.01 vs control). Coronary reperfusion with E6010 induced earlier recovery of left ventricular function than reperfusion with rt-PA or urokinase. These results suggest that E6010 may be of clinical value in the treatment of coronary occlusion.
AuthorsS Suzuki, M Saito, Y Yui, C Kawai
JournalJapanese circulation journal (Jpn Circ J) Vol. 59 Issue 4 Pg. 205-12 (Apr 1995) ISSN: 0047-1828 [Print] Japan
PMID7658613 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Recombinant Fusion Proteins
  • E 6010
  • Epidermal Growth Factor
  • Tissue Plasminogen Activator
Topics
  • Animals
  • Coronary Thrombosis (drug therapy)
  • Cricetinae
  • Disease Models, Animal
  • Dogs
  • Epidermal Growth Factor (administration & dosage, therapeutic use)
  • Female
  • Heart Diseases
  • Male
  • Mesocricetus
  • Recombinant Fusion Proteins (therapeutic use)
  • Reperfusion
  • Stroke Volume
  • Time
  • Tissue Plasminogen Activator (administration & dosage, therapeutic use)
  • Ventricular Function, Left (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: